Evidence map›Paper›PMID 35707461›Full record

ReviewFrontiers in endocrinology2022

LGR4, a G Protein-Coupled Receptor With a Systemic Role: From Development to Metabolic Regulation.

Joanna Filipowska, Nagesha G Kondegowda, Nancy Leon-Rivera, Sangeeta Dhawan, Rupangi C Vasavada

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Myeloid Cell-Specific Deletion of LGR4 Suppresses Atherosclerotic Lesion Formation.Arteriosclerosis, thrombosis, and vascular biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Alternative Polyadenylation Results in mRNA Transcript Instability in Gestational Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023
    Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Joanna FilipowskaDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute City of Hope, Duarte, CA, United States.
Nagesha G KondegowdaDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute City of Hope, Duarte, CA, United States.
Nancy Leon-RiveraDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute City of Hope, Duarte, CA, United States.
Sangeeta DhawanDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute City of Hope, Duarte, CA, United States.
Rupangi C VasavadaDepartment of Translational Research and Cellular Therapeutics, Arthur Riggs Diabetes and Metabolism Research Institute City of Hope, Duarte, CA, United States.
City of Hope · US

Funding

Renewal of the Human Islet Research Enhancement Center (HIREC) for the Type-1-Diabetes-Focused Human Islet Research Network (HIRN).U24DK104162 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI John S. Kaddis, Joyce Carol Niland · 2019 to 2026
$12.3M
Regulation of beta-cell homeostasis by DNA methylation and hydroxymethylation.R01DK120523 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI DHAWAN, SANGEETA · 2019 to 2023
$2.2M
Circulating Extracellular Vesicles in the Pathogenesis of Type 1 DiabetesR01DK125856 · NIDDK · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI SAHOO, SUSMITA, VASAVADA, RUPANGI C · 2021 to 2024
$1.8M
Osteoprotegerin and the Pancreatic Beta CellR01DK102893 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI VASAVADA, RUPANGI C · 2015 to 2018
$1.6M
NIDDK NIH HHS R01 DK102893NIDDK NIH HHS R01 DK120523NIDDK NIH HHS R01 DK125856NIDDK NIH HHS U24 DK104162
6 · The paper itself

Abstract

Leucine-rich repeat-containing G protein-coupled receptor 4 (LGR4/GPR48), a member of the GPCR (G protein-coupled receptors) superfamily, subfamily B, is a common intestinal crypt stem cell marker. It binds R-spondins/Norrin as classical ligands and plays a crucial role in Wnt signaling potentiation. Interaction between LGR4 and R-spondins initiates many Wnt-driven developmental processes, e.g., kidney, eye, or reproductive tract formation, as well as intestinal crypt (Paneth) stem cell pool maintenance. Besides the well-described role of LGR4 in development, several novel functions of this receptor have recently been discovered. In this context, LGR4 was indicated to participate in TGFβ and NFκB signaling regulation in hematopoietic precursors and intestinal cells, respectively, and found to be a new, alternative receptor for RANKL (Receptor Activator of NF kappa B Ligand) in bone cells. LGR4 inhibits the process of osteoclast differentiation, by antagonizing the interaction between RANK (Receptor Activator of NF kappa B) and its ligand-RANKL. It is also known to trigger anti-inflammatory responses in different tissues (liver, intestine, cardiac cells, and skin), serve as a sensor of the circadian clock in the liver, regulate adipogenesis and energy expenditure in adipose tissue and skeletal muscles, respectively. The extracellular domain of LGR4 (LGR4-ECD) has emerged as a potential new therapeutic for osteoporosis and cancer. LGR4 integrates different signaling pathways and regulates various cellular processes vital for maintaining whole-body homeostasis. Yet, the role of LGR4 in many cell types (e.g. pancreatic beta cells) and diseases (e.g., diabetes) remains to be elucidated. Considering the broad spectrum of LGR4 actions, this review aims to discuss both canonical and novel roles of LGR4, with emphasis on emerging research directions focused on this receptor.

Indexed as

Receptors, G-Protein-CoupledWnt Signaling PathwayLigandsNF-kappa BReceptor Activator of Nuclear Factor-kappa BStem CellsLigandsNF-kappa BReceptor Activator of Nuclear Factor-kappa BReceptors, G-Protein-CoupledGPCRs (G protein-coupled receptors)inflammationLGR4LGR4-ECDmiRNA34 a/cNFκB - Nuclear Factor κBRANKL (Receptor Activator for Nuclear Factor k B Ligand)Wnt signaling

Identifiers

PMID35707461
PMCPMC9190282
OpenAlexW4281814029

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.